Recent Updates
Recently added Catalysts

Sayana Press

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Aug 14, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment67
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04893798A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and AbdomenPHASE1 COMPLETED 67Sep 16, 2021Jul 24, 2025Aug 14, 20251 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Serum Trough Concentration (Ctrough) of Medroxyprogesterone
Day 92 post dose
Area under the curve from time zero to end of dosing interval (AUCtau)
pre-dose, up to 92 days post dose
Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone
pre-dose, up to 92 days post dose
Secondary Endpoints
Serum Progesterone Level
pre-dose, up to 99 days post dose
Serum Estradiol Level
pre-dose, up tp 99 days post dose
Serum Luteinizing Hormone (LH) Level
pre-dose, up to 99 days post dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
Sayana Press, Upper Arm injectionEXPERIMENTALSayana Press, administered subcutaneously into upper arm
Sayana Press, anterior thighACTIVE_COMPARATORSayana Press, administered subcutaneously into anterior thigh
Sayana Press, abdomenACTIVE_COMPARATORSayana Press, administered subcutaneously into abdomen
Interventions
NameTypeDescription
Sayana PressCOMBINATION_PRODUCTSayana Press is a drug-device combination and is considered a medical product in the EU.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Pre-menopausal female participants, 18 to 45 years of age, inclusive, at the time of signing the ICD who are at low risk of pregnancy * Participants who have a regular menstrual cycle (between 21 and 42 days in length). * No previous injection of depot MPA for 1 year prior to ...

Countries:Belgium
Unlock Eligibility Criteria